Microbial biofilms can present a variety of medical challenges by generating chronic infections, modulating host immune response, contaminating medical devices or environments, and facilitating the emergence of antimicrobial resistance.
Investigators at the Lewis Katz School of Medicine at Temple University have shown that a new monoclonal antibody treatment is able to break apart these communities of harmful bacteria, which could aid existing antibiotic treatments in more efficiently clearing out infections. Their research was published in Nature Communications.
The investigators tested a human monoclonal antibody with pan-amyloid-binding activity, mAb 3H3, against biofilms formed by Salmonella enterica serovar typhimurium.
The antibody was isolated from a healthy human subject. The study team was interested in 3H3’s ability to attach to β-amyloid.
FoodWorld 